Author: Ken Dropiewski

Translumina further strengthens Its technology portfolio with acquisition of Blue Medical Devices, Netherlands

The acquisition gives access to a patented, innovative, and proven next-generation Drug Coated Balloon (DCB) technology that may revolutionize the scope of complex coronary interventions NEW DELHI and HELMOND, Netherlands, June 29, 2023 /PRNewswire/ — Translumina, a global leader in Interventional Cardiovascular medical devices with manufacturing presence in Germany and India, today announced the acquisition of Blue […]

Rivus Pharmaceuticals Announces Leadership Transition, Appointment of Jayson Dallas, M.D., as CEO

–  Allen Cunningham appointed Chief Operating Officer, guiding execution of the company’s clinical programs for HU6 to treat cardiometabolic disease CHARLOTTESVILLE, Va. and SAN FRANCISCO, June 29, 2023 /PRNewswire/ — Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to improving cardiometabolic health, today announced the appointment of Jayson Dallas, M.D., executive chairman for Rivus Pharmaceuticals, as Chief Executive […]

Microbot Medical Successfully Completes an Extensive Pre-Clinical Study Performed in the US

HINGHAM, Mass., June 29, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic surgical system, today announced the successful completion of an extended pre-clinical study held by leading key opinion leaders (“KOLs”) at a New York-based research lab. […]

CorMedix Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Pre-Funded Warrants

BERKELEY HEIGHTS, N.J., June 28, 2023 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced the pricing of its previously announced underwritten public offering of 7,500,000 shares of its common […]

BioSig Joins Webull Corporate Connect

Webull’s investor community can now access real-time BioSig investor communications and Q&A Westport, CT, June 29, 2023 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it is now actively participating on the […]

Kalos Medical Receives Korean MFDS Innovative Medical Device Designation for DENEX Hypertension Treatment System

SEOUL, Korea, June 28, 2023 (GLOBE NEWSWIRE) — Kalos Medical Inc. (“Kalos Medical”), a developer of innovative medical devices treating hypertension and other chronic illnesses, announced on June 23rd that South Korea’s Ministry of Food and Drug Safety (“MFDS”) designated the company’s DENEX hypertension treatment system as an Innovative Medical […]

CathWorks Announces First Patient Enrolled in Global ALL-RISE Study

Global clinical study aims to broaden evidence base by assessing clinical and economic benefits for the FFRangio System First patient enrolled at Ascension St. John Hospital in Michigan KFAR-SABA, Israel and IRVINE, Calif., June 28, 2023 /PRNewswire/ — CathWorks announced today that the first patient has been enrolled in the Advancing Cath Lab Results with FFRangio Coronary Physiology […]

Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet

– Seeking inclusion of CV risk reduction indications in Europe –  – Anticipated approvals in Europe in the first half of 2024 –  ANN ARBOR, Mich., June 28, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that the application was filed for a Type II(a) variation with the European Medicines Agency (EMA) […]